Therapix Biosciences Ltd (TRPX):企業の財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(DATA904C4815)
◆英語タイトル:Therapix Biosciences Ltd (TRPX) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C4815
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年8月
◆ページ数:45
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥14,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥42,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Therapix Biosciences Ltd (TRPX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Therapix Biosciences Ltd (Therapix), formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central nervous system disorders. Therapix’s major product candidates include THX-110, for the treatment of tourette syndrome, obstructive sleep apnea and chronic pain; THX-130, for the treatment of mild cognitive impairment and traumatic brain injury; THX-150, for the treatment of infectious diseases; and THX-160, for the treatment of treat pain. The company conducts its clinical programs in collaboration with various pharma companies and institutions. Therapix Biosciences is headquartered in Tel Aviv, Israel.

Therapix Biosciences Ltd Key Recent Developments

Jul 12,2018: Cure acquires Therapix’s cannabinoid-based non-pain pipeline
Jul 11,2018: Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences
May 31,2018: Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update
May 15,2018: Therapix Biosciences Issues CEO’s Letter to Shareholders
May 09,2018: Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Therapix Biosciences Ltd – Key Facts 6
Therapix Biosciences Ltd – Key Employees 7
Therapix Biosciences Ltd – Key Employee Biographies 8
Therapix Biosciences Ltd – Major Products and Services 9
Therapix Biosciences Ltd – History 10
Therapix Biosciences Ltd – Locations And Subsidiaries 11
Head Office 11
Other Locations & Subsidiaries 11
Section 2 – Company Analysis 12
Company Overview 12
Therapix Biosciences Ltd – Business Description 13
Therapix Biosciences Ltd – Corporate Strategy 14
Therapix Biosciences Ltd – SWOT Analysis 15
SWOT Analysis – Overview 15
Therapix Biosciences Ltd – Strengths 15
Therapix Biosciences Ltd – Weaknesses 16
Therapix Biosciences Ltd – Opportunities 17
Therapix Biosciences Ltd – Threats 18
Therapix Biosciences Ltd – Key Competitors 19
Section 3 – Company Financial Ratios 20
Financial Ratios – Capital Market Ratios 20
Financial Ratios – Annual Ratios 21
Performance Chart 23
Financial Performance 23
Financial Ratios – Interim Ratios 24
Financial Ratios – Ratio Charts 25
Section 4 – Company’s Lifesciences Financial Deals and Alliances 26
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 27
Therapix Biosciences Ltd, Recent Deals Summary 28
Section 5 – Company’s Recent Developments 29
Jul 12, 2018: Cure acquires Therapix’s cannabinoid-based non-pain pipeline 29
May 31, 2018: Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update 30
May 15, 2018: Therapix Biosciences Issues CEO’s Letter to Shareholders 32
May 09, 2018: Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange 34
Jan 09, 2018: Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update at the Biotech Showcase 2018 35
Jan 09, 2018: Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update at the Biotech Showcase 2018 36
Nov 10, 2017: Therapix Biosciences Plans Preclinical Study to Evaluate Opioid-Sparing Effects of Two Innovative Synthetic Cannabinoids 37
Nov 09, 2017: Therapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update 38
Nov 07, 2017: Cure Pharmaceutical Enters Into Product Development Agreement with Therapix Biosciences To Develop Cannabinoid-Based Product For Sleep Disorders 39
Nov 02, 2017: Therapix Biosciences’ Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer 40
Section 6 – Appendix 41
Methodology 41
Ratio Definitions 41
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Therapix Biosciences Ltd, Key Facts 6
Therapix Biosciences Ltd, Key Employees 7
Therapix Biosciences Ltd, Key Employee Biographies 8
Therapix Biosciences Ltd, Major Products and Services 9
Therapix Biosciences Ltd, History 10
Therapix Biosciences Ltd, Subsidiaries 11
Therapix Biosciences Ltd, Key Competitors 19
Therapix Biosciences Ltd, Ratios based on current share price 20
Therapix Biosciences Ltd, Annual Ratios 21
Therapix Biosciences Ltd, Annual Ratios (Cont...1) 22
Therapix Biosciences Ltd, Interim Ratios 24
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 27
Therapix Biosciences Ltd, Recent Deals Summary 28
Currency Codes 41
Capital Market Ratios 41
Equity Ratios 42
Profitability Ratios 42
Cost Ratios 43
Liquidity Ratios 43
Leverage Ratios 44
Efficiency Ratios 44

List of Figures
Therapix Biosciences Ltd, Performance Chart (2013 - 2017) 23
Therapix Biosciences Ltd, Ratio Charts 25
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 27

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Therapix Biosciences Ltd (TRPX):企業の財務・戦略的SWOT分析(Therapix Biosciences Ltd (TRPX) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆